TrumpRx Weight-Loss Drug Deal Raises Questions for Insurance

The Trump administration’s deal to lower prices of popular weight-loss drugs is raising questions about whether the agreement includes prices for insurers and employers.

President Donald Trump on Thursday announced that Eli Lilly & Co. and Novo Nordisk A/S would reduce the prices of their GLP-1 weight-loss drugs in order to sell them through the president’s self-branded website, TrumpRx.

Prices for Lilly’s Zepbound will start at $299 for the lowest dose, $50 cheaper than it’s currently offered on Lilly’s direct-to-consumer site, LillyDirect. Prices for Wegovy will start at $350, according to the White House, compared to ...